Literature DB >> 26894782

Fluoropyrimidine and platinum toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Jared M Campbell1, Emma Bateman2, Micah Dj Peters1, Joanne M Bowen2, Dorothy M Keefe2, Matthew D Stephenson1.   

Abstract

Fluoropyrimidine (FU) and platinum-based chemotherapies are greatly complicated by their associated toxicities. This umbrella systematic review synthesized all systematic reviews that investigated associations between germline variations and toxicity, with the aim of informing personalized medicine. Systematic reviews are important in pharmacogenetics where false positives are common. Four systematic reviews were identified for FU-induced toxicity and three for platinum. Polymorphisms of DPYD and TYMS, but not MTHFR, were statistically significantly associated with FU-induced toxicity (although only DPYD had clinical significance). For platinum, GSTP1 was found to not be associated with toxicity. This umbrella systematic review has synthesized the best available evidence on the pharmacogenetics of FU and platinum toxicity. It provides a useful reference for clinicians and identifies important research gaps.

Entities:  

Keywords:  FU; adverse events; cancer; chemotherapy; fluoropyrimidine; personalized medicine; pharmacogenetics; pharmacogenomics; platinum; toxicity

Mesh：

Substances：

Year:  2016        PMID： 26894782     DOI： 10.2217/pgs.15.180

Source DB:  PubMed          Journal:  Pharmacogenomics        ISSN： 1462-2416            Impact factor:   2.533


  10 in total

Review 1.  DPYD Genotyping in Patients Who Have Planned Cancer Treatment With Fluoropyrimidines: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2021-08-12

Review 2.  Pharmacogenomics in Cytotoxic Chemotherapy of Cancer.

Authors:  Zahra Talebi; Alex Sparreboom; Susan I Colace
Journal:  Methods Mol Biol       Date:  2022

3.  Pharmacogenomic Profile of Amazonian Amerindians.

Authors:  Juliana Carla Gomes Rodrigues; Marianne Rodrigues Fernandes; André Maurício Ribeiro-Dos-Santos; Gilderlanio Santana de Araújo; Sandro José de Souza; João Farias Guerreiro; Ândrea Ribeiro-Dos-Santos; Paulo Pimentel de Assumpção; Ney Pereira Carneiro Dos Santos; Sidney Santos
Journal:  J Pers Med       Date:  2022-06-10

4.  The Role of Dihydropyrimidine Dehydrogenase and Thymidylate Synthase Polymorphisms in Fluoropyrimidine-Based Cancer Chemotherapy in an Iranian Population.

Authors:  Mohammad Hadi Abbasian; Nafiseh Ansarinejad; Bahareh Abbasi; Masoud Iravani; Tayeb Ramim; Fahime Hamedi; Ali M Ardekani
Journal:  Avicenna J Med Biotechnol       Date:  2020 Jul-Sep

Review 5.  Methodological approaches for assessing certainty of the evidence in umbrella reviews: A scoping review.

Authors:  Saranrat Sadoyu; Kaniz Afroz Tanni; Nontaporn Punrum; Sobhon Paengtrai; Warittakorn Kategaew; Nattiwat Promchit; Nai Ming Lai; Ammarin Thakkinstian; Surachat Ngorsuraches; Mukdarut Bangpan; Sajesh Veettil; Nathorn Chaiyakunapruk
Journal:  PLoS One       Date:  2022-06-08       Impact factor: 3.752

Review 6.  Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.

Authors:  J M Campbell; M D Stephenson; E Bateman; M D J Peters; D M Keefe; J M Bowen
Journal:  Pharmacogenomics J       Date:  2016-08-09       Impact factor: 3.550

7.  Case report: severe toxicity in an African-American patient receiving FOLFOX carrying uncommon allelic variants in DPYD.

Authors:  Tristan M Sissung; Lisa Cordes; Cody J Peer; Shruti Gandhy; Jason Redman; Julius Strauss; William D Figg
Journal:  Pharmacogenomics       Date:  2020-12-11       Impact factor: 2.533

8.  HLA-G 3'UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer.

Authors:  Marica Garziera; Saverio Virdone; Elena De Mattia; Lucia Scarabel; Erika Cecchin; Jerry Polesel; Mario D'Andrea; Nicoletta Pella; Angela Buonadonna; Adolfo Favaretto; Giuseppe Toffoli
Journal:  Int J Mol Sci       Date:  2017-06-27       Impact factor: 5.923

Review 9.  Toxicity and Pharmacogenomic Biomarkers in Breast Cancer Chemotherapy.

Authors:  Zeina N Al-Mahayri; George P Patrinos; Bassam R Ali
Journal:  Front Pharmacol       Date:  2020-04-15       Impact factor: 5.810

Review 10.  SNPs in predicting clinical efficacy and toxicity of chemotherapy: walking through the quicksand.

Authors:  Raffaele Palmirotta; Claudia Carella; Erica Silvestris; Mauro Cives; Stefania Luigia Stucci; Marco Tucci; Domenica Lovero; Franco Silvestris
Journal:  Oncotarget       Date:  2018-05-18
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.